Stock Track | Arcutis Biotherapeutics Soars Over 5% Premarket on Strong Q3 Results

Stock Track11-07 22:31

Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) saw its stock soar over 5% in premarket trading on November 7, 2024, following the release of its impressive third-quarter 2024 financial results. The biopharmaceutical company reported robust growth in its Zarife portfolio, driven by strong sales and expanded coverage.

The key highlights from Arcutis' Q3 2024 earnings report include: - Zarife portfolio sales grew a staggering 452% year-over-year and 45% quarter-over-quarter, reaching $44.8 million. - The company improved its gross-to-net percentages to the low 50% range, a significant improvement from the previous quarter's high 50s, indicating better profitability. - Arcutis secured Medicaid coverage in several states, representing roughly four in ten Americans, and is making progress with Medicare Part D programs.

According to Arcutis' President and CEO, Frank Watanabe, the company anticipates reaching breakeven by 2026 with its current capital and growing product revenues, without the need for additional equity financing. This positive outlook, coupled with the strong financial performance, has fueled investor confidence and contributed to the premarket surge in ARQT's stock price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126815994?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 22:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126815994","market":"us","top_or_hot":-1,"title":"Stock Track | Arcutis Biotherapeutics Soars Over 5% Premarket on Strong Q3 Results","media":"Stock Track","content":"<p>Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) saw its stock soar over 5% in premarket trading on November 7, 2024, following the release of its impressive third-quarter 2024 financial results. The biopharmaceutical company reported robust growth in its Zarife portfolio, driven by strong sales and expanded coverage.</p>\n\n<p>The key highlights from Arcutis' Q3 2024 earnings report include:\n- Zarife portfolio sales grew a staggering 452% year-over-year and 45% quarter-over-quarter, reaching $44.8 million.\n- The company improved its gross-to-net percentages to the low 50% range, a significant improvement from the previous quarter's high 50s, indicating better profitability.\n- Arcutis secured Medicaid coverage in several states, representing roughly four in ten Americans, and is making progress with Medicare Part D programs.</p>\n\n<p>According to Arcutis' President and CEO, Frank Watanabe, the company anticipates reaching breakeven by 2026 with its current capital and growing product revenues, without the need for additional equity financing. This positive outlook, coupled with the strong financial performance, has fueled investor confidence and contributed to the premarket surge in ARQT's stock price.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arcutis Biotherapeutics Soars Over 5% Premarket on Strong Q3 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arcutis Biotherapeutics Soars Over 5% Premarket on Strong Q3 Results\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-07 22:31 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) saw its stock soar over 5% in premarket trading on November 7, 2024, following the release of its impressive third-quarter 2024 financial results. The ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1126815994","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126815994","pubTimestamp":1730989895,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arcutis Biotherapeutics Inc.  saw its stock soar over 5% in premarket trading on November 7, 2024, following the release of its impressive third-quarter 2024 financial results. The biopharmaceutical company reported robust growth in its Zarife portfolio, driven by strong sales and expanded coverage.The key highlights from Arcutis' Q3 2024 earnings report include:. - Zarife portfolio sales grew a staggering 452% year-over-year and 45% quarter-over-quarter, reaching $44.8 million.- The company imp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Arcutis Biotherapeutics第三季度业绩强劲，盘前股价飙升超过5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARQT":1},"content_text":"Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) saw its stock soar over 5% in premarket trading on November 7, 2024, following the release of its impressive third-quarter 2024 financial results. The biopharmaceutical company reported robust growth in its Zarife portfolio, driven by strong sales and expanded coverage.\nThe key highlights from Arcutis' Q3 2024 earnings report include:\n- Zarife portfolio sales grew a staggering 452% year-over-year and 45% quarter-over-quarter, reaching $44.8 million.\n- The company improved its gross-to-net percentages to the low 50% range, a significant improvement from the previous quarter's high 50s, indicating better profitability.\n- Arcutis secured Medicaid coverage in several states, representing roughly four in ten Americans, and is making progress with Medicare Part D programs.\nAccording to Arcutis' President and CEO, Frank Watanabe, the company anticipates reaching breakeven by 2026 with its current capital and growing product revenues, without the need for additional equity financing. This positive outlook, coupled with the strong financial performance, has fueled investor confidence and contributed to the premarket surge in ARQT's stock price.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126815994"}